← FDA DRUG APPROVALS

FDA NDA · NDA206317

TRIFERIC

Sponsor: ROCKWELL MEDICAL INC

APPLICATION
NDA206317
TYPE
NDA
ORIGINAL APPROVAL
2015-01-23
LATEST ACTION
2019-07-10
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

TRIFERIC · ReferenceDiscontinued
FERRIC PYROPHOSPHATE CITRATE 27.2MG IRON/5ML (5.44MG IRON/ML) · SOLUTION · INTRAVENOUS
TRIFERIC · ReferenceDiscontinued
FERRIC PYROPHOSPHATE CITRATE 272MG IRON/50ML (5.44MG IRON/ML) · SOLUTION · INTRAVENOUS

Approval history

2019-07-10Labeling · Supplement 12 · standardLetterAP
2018-03-29Labeling · Supplement 10 · standardLabelAP
2017-10-16Labeling · Supplement 9 · standardLabelAP
2016-07-28Manufacturing (CMC) · Supplement 7 · standardAP
2016-05-16Manufacturing (CMC) · Supplement 3 · standardAP
2015-11-12Manufacturing (CMC) · Supplement 4 · standardAP
2015-09-10Manufacturing (CMC) · Supplement 2 · standardAP
2015-01-23Type 5 - New Formulation or New Manufacturer · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →